Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-12
2010-11-09
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07829528
ABSTRACT:
The present invention relates to a cell permeable peptide to specifically inhibit tyrosine phosphorylation and/or subsequent activation of STAT-6. This peptide is composed of a protein transduction moiety operably linked to a portion of STAT-6 which contains tyrosine residue 641 (Tyr-641) of STAT-6, wherein Tyr-641 is phosphorylated. The chimeric STAT-6 peptide enters cells and binds to the SH2 domain of wild-type STAT-6, and subsequently inhibits dimerization and nuclear translocation of the wild-type STAT-6 protein. Administration of this chimeric peptide inhibits allergen-induced airway inflammation, cytokine production and airway hyperresponsiveness and is useful in methods for preventing or treating diseases or conditions associated with STAT-6 activation.
REFERENCES:
patent: 6207391 (2001-03-01), Wu et al.
patent: 6368828 (2002-04-01), LaRochelle et al.
patent: 6426331 (2002-07-01), McKinney et al.
patent: 2003/0186841 (2003-10-01), Barhas, III et al.
patent: WO0183517 (2001-11-01), None
patent: WO0238107 (2002-05-01), None
Lu et al. 1997; Identification of STAT6 domain required for IL-4 activation of transcription. Journal of Immunology. 159: 1255-1264.
Calo et al., “STAT Proteins:From Normal Control of Cellular Events to Tumorigenesis”, Journal of Cellular Physiology 2003 197:157-168.
Heim et al., “Contribution of STAT SH2 Groups to Specific Interferon Signaling by the Jak-STAT Pathway”, Science 1995 267:1347-1349.
Khurana et al., “IL-13 receptors and signaling pathways:An evolving web”, J. Allergy Clin Immunol 2003 111:677-690.
Hirayama et al., “Inhibition of Inflammatory Bone Erosion by Constitutively Active STAT-6 Through Blockade of JNK and NF-kB Activation”, Arthritis & Rheumatism 2005 52(9):2719-2729.
Ho et al., “Synthetic Protein transduction Domains:Enhanced Transduction Potential in Vitro and in Vivo”, Cancer Research 2001 61:474-477.
Songyang at al., SH2 Domains Recognize Specific Phosphopeptide Sequences, Cell 1993 72:767-778.
Stolzenberger et al., “Specific inhibition of interleukin-4-dependent Stat6 activation by an intracellularly delivered peptide”, Eur. J. Biochem. 2001 268:4809-4814.
Fixman Elizabeth D.
McCusker Christine T.
Carlson Karen Cochrane
Licata & Tyrrell P.C.
The Rockefeller University
LandOfFree
Compositions and methods for treating STAT-6 associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating STAT-6 associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating STAT-6 associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214309